Web19 jan. 2024 · Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality. With an increase in life expectancy, the economic burden of IPF is expected to continuously rise in the near future. Web26 dec. 2024 · In IPF patients aged ≥56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42-49]) compared to non-carriers (29 months [CI: 26-33]; p = 4 × 10-12 ). CONCLUSION: MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years.
Genetic associations and lung function in IPF: unexpected answers ...
Web17 okt. 2011 · The MUC5B mutation was confirmed in an independent case-control study ( 3) that included 341 IPF and 801 control subjects evaluated at the University of Pittsburgh and the University of Chicago using a different genotyping platform. WebThe MUC5B promoter variant is the strongest known risk factor for the development of IPF, with homozygotes for the polymorphism having a 20-fold increased risk of IPF and heterozygotes having a sevenfold increase in risk. smallrig adjustable camera monitor mount
Frontiers Mucus Hypersecretion and Ciliary Impairment in …
WebLearn about idiopathic pulmonary fibrosis. Skip to Main Content PFF Help Center(844) 825-5733 FacebookTwitterLinkedInYouTubeInstagram Join the PFF RegistryDonate Shop PFF Menu To navigate the following site navigation expect to utilize the tab key to move through items sequentially. Web12 apr. 2024 · Besides, MUC5B promoter variant rs35705950 is a high-risk factor for IPF 11, the cluster A exhibited higher MUC5B expression than B. These results suggested that cluster A was related to IPF. WebIPF is a progressive disease which is thought to occur after recurrent injury to the alveolar epithelium followed by dysregulation of cellular homoeostasis, abnormal repair and excessive deposition of extracellular matrix, ultimately leading to loss of lung function. 1 Mortality 3–5 years after diagnosis of IPF is 50%, and treatment options are … hilbert heated gloves